Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study (P10-2.004)
Knievel, Kerry, McVige, Jennifer , Wang, Weiying , Gillard, Patrick, Shah, Darshini, Blumenfeld, Andrew , Schwedt, Todd J. , Lee, Jae Hyun, Wu, Zheng

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.716 Get It

The Effect of Pharmacogenomic Data on Adequate Dosages of Verapamil for The Prevention of Primary Headache Disorders-a pilot exploratory study (P11-2.004)
Chen, Yi‐Chieh , Wang, Han , Mandrekar, Jayawant N. , Starling, Amaal J. , Cutrer, F. Michael , Robertson, Carrie E. , Chiang, Chia‐Chun

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2390 Get It

Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal
Raynaud, Marc , Awadhi, Solaf Al, Louis, Kévin , Zhang, Huanxi , Su, Xiaojun , Goutaudier, Valentin , Wang, Jiali, Demir, Zeynep , Wei, Yongcheng , Truchot, Agathe , Bouquegneau, Antoine , Bailly, É. , Maanaoui, Mehdi , Naser, Sofía , Wang, Changxi , Liu, Longshan , Lefaucheur, Carmen , Riella, Leonardo V. , Collins, Professor Gary S. , Al-Awadhi, Solaf , Bailly, Élodie , Lombardi, Yannis , Giarraputo, Alessia , Naser, Sofia , Divard, Gillian , Aubert, Olivier , Murad, M Hassan , Liu, Longshan , Bestard, Oriol , Naesens, Maarten , Friedewald, John J , Lefaucheur, Carmen , Riella, Leonardo V , Collins, Gary , Ioannidis, John P A , Loupy, Alexandre , Bello, Arnaud Del , Divard, Gillian , Murad, M. Hassan , Bestard, Oriol , Naesens, Maarten , Friedewald, John J. , Ioannidis, John P. A. , Loupy, Alexandre

Mayo Clinic

Journal of the American Society of Nephrology | December 6, 2023 | Volume: 35 | Issue: 2 | Pages: 177-188

10.1681/asn.0000000000000260 | PMID 38053242 Get It

Significance Statement Why are there so few biomarkers accepted by health authorities and implemented in clinical practice, despite the high and growing number of biomaker studies in medical research ? In this meta-epidemiological study, including 804 studies that were critically appraised by expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient monitoring parameters. Most biomarker studies tended to be single-center, retrospective studies with a small number of patients and clinical events. Less than 5% of the studies performed an external validation. The authors also showed the poor transparency reporting and identified a data beautification phenomenon. These findings suggest that there is much wasted research effort in transplant biomarker medical research and highlight the need to produce more rigorous studies so that more biomarkers may be validated and successfully implemented in clinical practice. Background Despite the increasing number of biomarker studies published in the transplant literature over the past 20 years, demonstrations of their clinical benefit and their implementation in routine clinical practice are lacking. We hypothesized that suboptimal design, data, methodology, and reporting might contribute to this phenomenon. Methods We formed a consortium of experts in systematic reviews, nephrologists, methodologists, and epidemiologists. A systematic literature search was performed in PubMed, Embase, Scopus, Web of Science, and Cochrane Library between January 1, 2005, and November 12, 2022 (PROSPERO ID: CRD42020154747). All English language, original studies investigating the association between a biomarker and kidney allograft outcome were included. The final set of publications was assessed by expert reviewers. After data collection, two independent reviewers randomly evaluated the inconsistencies for 30% of the references for each reviewer. If more than 5% of inconsistencies were observed for one given reviewer, a re-evaluation was conducted for all the references of the reviewer. The biomarkers were categorized according to their type and the biological milieu from which they were measured. The study characteristics related to the design, methods, results, and their interpretation were assessed, as well as reproducible research practices and transparency indicators. Results A total of 7372 publications were screened and 804 studies met the inclusion criteria. A total of 1143 biomarkers were assessed among the included studies from blood ( n =821, 71.8%), intragraft ( n =169, 14.8%), or urine ( n =81, 7.1%) compartments. The number of studies significantly increased, with a median, yearly number of 31.5 studies (interquartile range [IQR], 23.8–35.5) between 2005 and 2012 and 57.5 (IQR, 53.3–59.8) between 2013 and 2022 ( P < 0.001). A total of 655 studies (81.5%) were retrospective, while 595 (74.0%) used data from a single center. The median number of patients included was 232 (IQR, 96–629) with a median follow-up post-transplant of 4.8 years (IQR, 3.0–6.2). Only 4.7% of studies were externally validated. A total of 346 studies (43.0%) did not adjust their biomarker for key prognostic factors, while only 3.1% of studies adjusted the biomarker for standard-of-care patient monitoring factors. Data sharing, code sharing, and registration occurred in 8.8%, 1.1%, and 4.6% of studies, respectively. A total of 158 studies (20.0%) emphasized the clinical relevance of the biomarker, despite the reported nonsignificant association of the biomarker with the outcome measure. A total of 288 studies assessed rejection as an outcome. We showed that these rejection studies shared the same characteristics as other studies. Conclusions Biomarker studies in kidney transplantation lack validation, rigorous design and methodology, accurate interpretation, and transparency. Higher standards are needed in biomarker research to prove the clinical utility and support clinical use.
Minimally Invasive Quadriceps Tendon Harvest for Anterior Cruciate Ligament Reconstruction Using the Quadriceps Tendon Harvest Guide (QUADTRAC) System and Repair Augmentation With a Bioinductive Implant
Wang, Allen S. , Boos, Alexander M. , Dancy, Malik E. , Camp, Christopher L. , Hevesi, Mario , Okoroha, Kelechi R. , Camp, Christopher L. , Wang, Allen , Boos, Alexander , Hevesi, Mario

Mayo Clinic

Arthroscopy Techniques | December 4, 2023 | Volume: 13 | Issue: 1 | Pages: No page available

10.1016/j.eats.2023.08.017 | PMID 38312883 Get It

Abstract Quadriceps tendon autografts are an increasingly popular choice for anterior cruciate ligament (ACL) reconstruction, with decreased donor‐site morbidity alongside good patient outcomes. Although harvesting of the tendon can be done in a minimally invasive fashion, this introduces some difficulty with visualization and consistency of graft sizing. The purpose of this Technical Note and video is to provide a method of quadriceps tendon autograft harvesting using the Quadriceps Tendon Harvest Guide System (QUADTRAC) in a single‐bundle ACL reconstruction. Technique Video video See video under supplementary data.
Does diabetes affect outcome or reoperation rate after lumbar decompression or arthrodesis? A matched analysis of the Quality Outcomes Database data set
Mooney, James , Zeitouni, Daniel , Michalopoulos, Giorgos D. , Wang, Michael Y. , Coric, Domagoj , Chan, Andrew K. , Lu, Daniel C. , Sherrod, Brandon A. , Gottfried, Oren N., Shaffrey, Christopher I. , Than, Khoi D. , Hussain, Ibrahim , Virk, Michael S. , Glassman, Steven D. , Shaffrey, Mark E., Foley, Kevin T. , Chou, Dean , Slotkin, Jonathan R., Tumialán, Luis M. , Upadhyaya, Cheerag D., Potts, Eric A. , Fu, Kai-Ming, Haid, Regis W., Knightly, John J. , Mummaneni, Praveen V. , Bisson, Erica F. , Asher, Anthony L. , Bydon, Mohamad , Michalopoulos, Giorgos , Nathani, Karim Rizwan , Goldberg, Jacob L. , Agarwal, Nitin , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | December 2, 2023 | Volume: 40 | Issue: 3 | Pages: 331-342

10.3171/2023.9.spine23522 | PMID 38039534 Get It

OBJECTIVE Diabetes mellitus (DM) is a known risk factor for postsurgical and systemic complications after lumbar spinal surgery. Smaller studies have also demonstrated diminished improvements in patient-reported outcomes (PROs), with increased reoperation and readmission rates after lumbar surgery in patients with DM. The authors aimed to examine longer-term PROs in patients with DM undergoing lumbar decompression and/or arthrodesis for degenerative pathology. METHODS The Quality Outcomes Database was queried for patients undergoing elective lumbar decompression and/or arthrodesis for degenerative pathology. Patients were grouped into DM and non-DM groups and optimally matched in a 1:1 ratio on 31 baseline variables, including the number of operated levels. Outcomes of interest were readmissions and reoperations at 30 and 90 days after surgery in addition to improvements in Oswestry Disability Index, back pain, and leg pain scores and quality-adjusted life-years at 90 days after surgery. RESULTS The matched decompression cohort comprised 7836 patients (3236 [41.3] females) with a mean age of 63.5 ± 12.6 years, and the matched arthrodesis cohort comprised 7336 patients (3907 [53.3%] females) with a mean age of 64.8 ± 10.3 years. In patients undergoing lumbar decompression, no significant differences in nonroutine discharge, length of stay (LOS), readmissions, reoperations, and PROs were observed. In patients undergoing lumbar arthrodesis, nonroutine discharge (15.7% vs 13.4%, p < 0.01), LOS (3.2 ± 2.0 vs 3.0 ± 3.5 days, p < 0.01), 30-day (6.5% vs 4.4%, p < 0.01) and 90-day (9.1% vs 7.0%, p < 0.01) readmission rates, and the 90-day reoperation rate (4.3% vs 3.2%, p = 0.01) were all significantly higher in the DM group. For DM patients undergoing lumbar arthrodesis, subgroup analyses demonstrated a significantly higher risk of poor surgical outcomes with the open approach. CONCLUSIONS Patients with and without DM undergoing lumbar spinal decompression alone have comparable readmission and reoperation rates, while those undergoing arthrodesis procedures have a higher risk of poor surgical outcomes up to 90 days after surgery. Surgeons should target optimal DM control preoperatively, particularly for patients undergoing elective lumbar arthrodesis.
Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Multicenter Analysis
Vuyyala, Sowjanya, Corraes, Andre De Menezes Silva , Bailey, Megumi, Hunter, Bradley D. , Bansal, Radhika , Kharfan‐Dabaja, Mohamed A. , Johnston, Patrick B. , Villasboas, J. C. C, Ansell, Stephen M. , Khurana, Arushi , Iqbal, Madiha , Muñoz, Javier , Patel, Krish , Rosenthal, Allison , Wang, Yucai , Paludo, Jonas , Bennani, N. Nora , Durani, Urshila , Lin, Yi

Mayo Clinic

Blood | December 2, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 6926-6926

10.1182/blood-2023-188441 Get It

Introduction: In Cohorts 1+2 of the ZUMA-1 Phase 1/2 study of axi-cel in R/R LBCL, 11% and 31% of patients (pts) experienced Grade ≥3 cytokine release syndrome (CRS) or neurologic evenets), respectively. To minimize the toxicities seen with axi-cel, a safety management cohort, Cohort 6 (N=40), was added to evaluate whether prophylactic (ppx) corticosteroids (CS) could decrease grade ≥ 3 CRS or ICANS. The 2-year update of ZUMA-1 Cohort 6 showed no grade ≥3 CRS and 15% grade ≥3 ICANS without any difference in objective response rate (ORR) or complete response rate (CR) when compared to cohorts 1+2 (Oluwole Blood 2022). The FDA had previously approved an update to the prescribing information for axi-cel to include use of ppx CS across all approved indications in January 2022. However, ppx CS is not a mandatory standard treatment and we sought to establish the clinical outcomes in the real-world practice. Methods: To assess the clinical outcomes of pts receiving ppx CS, we conducted a multicenter retrospective analysis of pts with R/R LBCL who were treated with axi-cel since the FDA approval of ppx CS in January 2022. Baseline characteristics, toxicities, and efficacy were compared between the no ppx and ppx CS groups. CRS and ICANS were graded based on ASTCT 2019 guidelines. Event-free survival (EFS) was defined as time from axi-cel infusion to progression, re-treatment, or death. Overall survival (OS) was defined as time from axi-cel infusion to death due to any cause. Results: A total of 66 pts at 5 centers received axi-cel between Jan 31, 2022, and June 20, 2023. Thirty-five (52%) pts received ppx CS, with a median age of 63 years (26-85 years). By histology, 75% (n=50) of the pts had DLBCL, 13.6% (n=9) had high grade B-cell lymphoma (HGBL), 9.1% (n=6) had transformed follicular lymphoma (TFL) and 1.5% (n=1) primary mediastinal LBCL (PMBCL). 59% of the pts (n=37) had IPI &gt;2 and 66% (n=43) had stage III/IV disease. The baseline characteristics at the time of apheresis are shown in Table 1 and were comparable between the 2 groups, except for more HGBL, fewer prior lines of therapy and longer median time from apheresis to axi-cel infusion in the ppx CS group. Among the entire cohort, only 37% (n=25) met ZUMA-1 eligibility criteria at the time of lymphodepletion, and 67% (n=44) needed bridging therapy. Any grade CRS occurred in 88% (n=58) of the pts, with grade ≥2 CRS in 38% (n=25). Any grade ICANS occurred in 55% (n=37) of the pts, with grade ≥2 ICANS in 41% (n=27). Any grade ICANS was significantly lower in the ppx CS group than the no ppx group (45.7% vs 65.5%). The rates of any grade CRS, grade ≥2 CRS, grade ≥2 ICANS, the median time to CRS onset, ICANS onset, CRS duration, and ICANS duration were comparable between the 2 groups. Tocilizumab and steroids use was similar between two groups with a trend towards less ICU admission in patients in the ppx CS group. Overall, 14 (21%) pts developed infectious complications within 30 days of axi-cel infusion. The day 30 ORR was 84% and was comparable between the 2 groups (77% in the ppx group vs 93% in the no ppx group). The CR was 45.7% in ppx CS group compared to 65.5% in no ppx group. At a median follow up of 219 days (27-1178), 37 (56.1%) pts had progressed and 25 (37.9%) pts had died. The number of days to progress was significantly lower in the ppx CS arm. The median EFS and OS were not significant between the 2 groups. Conclusions: This multicenter retrospective study showed that the efficacy of treatment with axi-cel in R/R LBCL did not decrease with the use of ppx CS. No significant differences in efficacy or CAR-T-associated toxicities were noted in the 2 groups, potentially due to selective use with patients at presumed higher risk of severe CRS and ICANS. A larger dataset and longer follow-up is needed for risk-stratified analysis and the study is ongoing.